faqs  investors  gi dynamicscontact usselect pagefaqsfounded in  gi dynamics inc gi dynamics or the company is headquartered in lexington massachusetts in the united states on september   trading in chess depositary interests cdis of gi dynamics commenced on the australian securities exchange asx under the stock ticker gid to assist all shareholders of gi dynamics a list of frequently asked questions is set out below important notice the information in this document does not take into account your individual investment objectives financial situation and needs the information in this document is of a general nature and is not financial product advice and should not be relied upon as the sole basis for any investment decision shareholders should consult their financial legal or tax adviser before deciding to buy or sell cdis in gi dynamics your adviser may ask you for the gi dynamics’ isin number for your reference gi dynamics’ isin number is augiddisplay all answerswhat is a chess depositary interest or cdithe electronic transfer system used on asx known as chess cannot be used directly for the transfer of securities of foreign companies accordingly to enable companies such as gi dynamics to have their securities cleared and settled electronically through chess depositary instruments called chess depositary interests cdis are issuedwhat is a share of common stockshares of common stock are the us equivalent of ordinary shares in an australian company gi dynamics is incorporated in the united states and hence has common stock on issuewhat is the ratio of shares of common stock to cdiseach cdi represents an interest in th of an underlying share of gi dynamics’ common stockhow is gi dynamics’ common stock heldin the united states your common stock is held on either a certificated basis or an uncertified bookentry basis the american stock transfer  trust company llc ast is the transfer agent for the company’s common stockhow are gi dynamics’ cdis heldin australia cdis are held on an uncertificated basis holders of cdis will be issued a holding statement which will set out details of the number of cdis you hold in gi dynamics and an identification reference there are no physical share certificates issued link market services limited is the company’s share registry for cdis listed in australiacan i convert my cdis into common stock what forms do i need and is there a feeyes you can convert some or all of your cdis into common stock at any time cdi holders who wish to convert their asxlisted cdis to shares of common stock can do so by instructing the company’s share registry link market services limited eitherdirectly in the case of cdis on the issuer sponsored subregister operated by the company cdi holders will be provided with a “notice of transmutation” for completion and return to the company’s share registry orthrough their sponsoring participant usually their broker in the case of cdis that are sponsored on the chess subregister in this case the sponsoring broker will arrange for completion of the relevant form and its return to the company’s share registry the company’s share registry will then arrange for the shares underlying the cdis which are to be converted to be transferred into the name of that holder and a bookentry advice which will set out details of the number of shares of common stock you hold in gi dynamics will be issued by american stock transfer  trust company llc who is the transfer agent for the companys common stock this will cause the shares to be registered in the name of the holder on the company’s share register and trading on asx will no longer be possible the shares are not and will not in the near future be quoted on any market in the us or elsewhere any shares so issued will bear restrictive legends in accordance with us law the company’s share registry will not charge an individual security holder a fee for converting cdi holdings into shares although a fee will be payable by market participants it is expected that this process will be completed within  days provided that the share registry is in receipt of a duly completed and valid notice of transmutation however no guarantee can be given about the time for this conversion to take place if the shares are listed on a us securities exchange in the future a fee may be payable for entering the shares into the dtc or drs system contact link market services by facsimile to    within australia or     outside australia by mail to link market services limited locked bag a sydney south nsw  australia telephone enquiries by you or your broker    toll free within australia     outside australia on the web wwwlinkmarketservicescomau email registrarslinkmarketservicescomaucan i convert common stock into cdis what forms do i need and is there a feeyes you can convert some or all of your shares of common stock into cdis at any time if holders of the common stock shares wish to convert their holdings to cdis they can do so by contacting the company’s us transfer agent american stock transfer  trust company llc ast for the common stock ast will provide shareholders with a “notice of transmutation” for completion and return to ast which will ultimately also be provided to the company’s share registry link market services limited to complete the process a fee will not be charged to a holder of shares seeking to convert the shares to cdis although a fee will be payable by market participants contact ast by mail to american stock transfer  trust company llc po box  new york new york  telephone enquiries by you or your broker  toll free within us or  on the web wwwamstockcom email infoamstockcomwhat is gi dynamics isin number gi dynamics’ isin number is augid are my cdis freely tradable on asx what is the “for us” designationyes your cdis are freely tradable on asx except to us persons who are not currently permitted to acquire cdis in gi dynamics the cdis issued to investors under the public offer were issued in reliance on the exemption from registration contained in regulation s of the us securities act of  for offers made outside the us accordingly the cdis have not been registered under the us securities act or the laws of any state or jurisdiction of the us as a result the cdis are restricted securities and cannot be sold into the us or to a us person for a period of  months from the date of allotment unless the cdis are registered or an exemption is available in order to ensure that us persons do not purchase any cdis issued under the public offer a number of procedures governing the trading and clearing of cdis have been implemented including the application to cdis of the status of foreign ownership restriction for securities under the asx settlement operating rules and the addition of the notation for us to the cdi description on asx trading screens and elsewhere which will inform the market of the prohibition on us persons acquiring cdis where can i access the current stock price for asxgi dynamics’ asx price for cdis is available at wwwasxcomau or via the overview page in the investors section of this websitehow do new investors buy gi dynamics securitiesnew investors can buy cdis on the asx through an australian broker investors may then convert between cdis and common stock as described in questions  and  above when is the asx market openthe asx is open for trading from am to pm australian eastern standard time aest on monday to friday excluding public holidayshow do i receive gi dynamics’ announcements on asxannouncements will be posted on the asx wwwasxcom and to the asx announcements section of this website announcements and all press releases can be accessed on this website or by subscribing to receive them by email when they are posted see email alert section of investor pages on website cdi holders will automatically receive all documents mailed to shareholders including the annual report incorporating gi dynamics audited financial results for each financial year and documentation relating to shareholder meetingswho maintains the companys share register and how do i contact themlink market services limited is managing the register of holders of cdis contact numbers are set out below link market services by facsimile to    within australia or     outside australia by mail to link market services limited locked bag a sydney south nsw  australia telephone enquiries by you or your broker    toll free within australia     outside australia on the web wwwlinkmarketservicescomau email registrarslinkmarketservicescomau american stock transfer  trust company llc ast is the transfer agent managing the register of holders of common stock contact numbers are set out belowast by mail to american stock transfer  trust company llc po box  new york new york  telephone enquiries by you or your broker  toll free within us or  on the web wwwamstockcomhow do i check my holding in gi dynamicsif you are a cdi holder you can refer to the last holding statement you received or if you are a chess sponsored holder contact your broker you can also check these details online at wwwlinkmarketservicescomau by selecting ‘investor login’ you will need your securityholder reference number srn or holder identification number hin and your postcode to access your details alternatively you can contact link market services either by phone or email using the details set out below tel    toll free within australia tel     outside australia email registrarslinkmarketservicescomau if you are a holder of common stock you will need to contact american stock transfer  trust company llc ast to confirm your holding details you can check these details either by going online at wwwamstockcom or by phone or email using the details set out below telephone enquiries by you or your broker  toll free within us or  email infoamstockcomhow do i change or update any details of my holding such as a change of addresscdi holders can download forms for updating details including change of address from wwwlinkmarketservicescomau individual holders can also update these details directly online as long as their holding is valued at less than  forms can also be requested over the phone by calling tel    toll free within australia tel     outside australiaimportant chess sponsored holders will need to notify their broker of any change of address if you are a holder of common stock you will need to contact american stock transfer  trust company llc ast to request a form to update your details ast can be contacted using the details set out below tel  toll free within us or  email infoamstockcom online wwwamstockcomwhen will gi dynamics’ stockholder meetings be held in the future gi dynamics intends to hold its annual general meetings in may each year gid will announce the details and locations of those meetings in advance all stockholders are invited to attend these meetings will also be webcast and accessible worldwide how do i vote at those stockholder meetings instructions for voting common stock or cdis will be contained in the proxy statement notice of meeting provided to stockholders and cdi holders prior to the annual general meeting do i have to pay tax when my shares are converted from cdis into common stock and vice versa in general terms gi dynamics does not expect that stockholders will trigger a taxable event when converting between cdis and common stock and vice versa provided the legal and beneficial ownership stays the same please consult your personal tax adviser in relation to your own situation will gi dynamics report quarterly earnings gi dynamics will report quarterly earnings following the close of each quarter and fiscal year the appendix c filings the asx quarterly results announcements for each quarter will be filed with the asx and made available on the asx announcements and annual  quarterly reports pages of this websitewho is gi dynamics’ auditor gi dynamics’ auditor is moody famiglietti  andronico llpwho is gi dynamics’ legal counsel in australia gi dynamics’ legal adviser is kpmg law in the us gi dynamics’ legal adviser is mintz levin cohn ferris glovsky and popeo pc kpmg law  shelley street sydney nsw  australia mintz levin cohn ferris glovsky and popeo pc one financial center boston ma  united states javascript is not enabled with javascript enabled this page will display content dynamicallyprint pageemail pagerss feedsemail alerts product overview  gi dynamics contact us select page product overview pioneering treatment for diabetes  obesity videos bbc news item endobarrier treatment for obstructive sleep apnoea – nd abcd endobarrier study abcd endobarrier study year results including year cv risk assessment – robert ryder md  product overview pioneering treatment for diabetes  obesity gi dynamics inc gid  product pipeline analysis  update infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports gi dynamics inc gid  product pipeline analysis  gi dynamics inc gid  product pipeline analysis  update wgr  september  global  pages globaldata description table of content sample report enquiry before buy related reports summarygi dynamics inc gi dynamics is a medical device company the company develops and commercializes nonsurgical treatments for the global patient population suffering with type  diabetes and obesity its product endobarrier therapy is used for the treatment of type  diabetes and obesity gi dynamics conducts clinical trial of endobarrier the endo trial in the us the company’s product lowers blood glucose levels and promotes weight loss in diabetic patients andor obese patients during the implant period it sells products in europe south america and australia gi dynamics is headquartered in lexington massachusetts the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments the report analyzes all pipeline products in development for the company gi dynamics inc the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date the report provides detailed description of products in development technical specification and functions the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape design and develop your product development marketing and sales strategies by understanding the competitor portfolio to formulate effective research  development strategies develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc identify understand and capitalize the next highvalue products that your competitor would add in its portfolio table of contents table of contents list of tables list of figures gi dynamics inc company snapshot gi dynamics inc company overview key information gi dynamics inc pipeline products and clinical trials overview gi dynamics inc – pipeline analysis overview key facts gi dynamics inc  major products and services gi dynamics inc pipeline products by development stage gi dynamics inc clinical trials by trial status gi dynamics inc pipeline products overview endobarrier flow restrictor endobarrier flow restrictor product overview endobarrier flow restrictor clinical trial endobarrier gastrointestinal liner endobarrier gastrointestinal liner product overview endobarrier gastrointestinal liner clinical trial endobarrier liner with endobarrier restrictor endobarrier liner with endobarrier restrictor product overview gi dynamics inc  key competitors gi dynamics inc  key employees gi dynamics inc  locations and subsidiaries head office other locations  subsidiaries recent developments gi dynamics inc recent developments aug   gi dynamics announces the appointment of medical device industry veteran michael d dale as president  chief executive officer jul   gi dynamics announces launch of endobarrier therapy clinical utility study in france jul   gi dynamics announces departure of chief commercial officer jun   data presented at ada show the effects of gi dynamics’ endobarrier therapy on glycemic control and reducing diabetes medication in patients with type  diabetes and obesity may   gi dynamics announces new findings that show elimination of and reduced reliance on insulin by patients treated with endobarrier therapy may   gi dynamics announces new endobarrier data from research with glaxosmithkline presented during digestive disease week apr   gi dynamics expands availability of endobarrier therapy in australia in two additional cities feb   gi dynamics announces expanded reimbursement coverage in germany nov   gi dynamics announces endobarrier therapy data to be presented at obesity week oct   gi dynamics to participate in diabetes treatment panel discussion at cleveland clinic’s th annual medical innovation summit appendix methodology about globaldata contact us disclaimer list of tables gi dynamics inc key facts gi dynamics inc pipeline products and clinical trials overview gi dynamics inc pipeline products by equipment type gi dynamics inc pipeline products by indication gi dynamics inc clinical trials by trial status gi dynamics inc key facts gi dynamics inc major products and services gi dynamics inc number of pipeline products by development stage gi dynamics inc pipeline products summary by development stage gi dynamics inc clinical trials by trial status gi dynamics inc clinical trials summary endobarrier flow restrictor  product status endobarrier flow restrictor  product description endobarrier flow restrictor  twoyear clinical utility study of endobarrier therapy endobarrier gastrointestinal liner  product status endobarrier gastrointestinal liner  product description endobarrier gastrointestinal liner  a pilot trial of the gi endobarrier liner for short term weight loss in subjects who are candidates for bariatric surgery endobarrier gastrointestinal liner  a pivotal clinical trial for endobarrier in patients with uncontrolled type  diabetes endobarrier gastrointestinal liner  a randomized multicenter pivotal efficacy and safety study comparing the endobarrier gastrointestinal liner system versus sham for glycemic improvement in inadequately controlled obese type  diabetic subjects on metformin andor sulfonylurea antidiabetes agents endobarrier gastrointestinal liner  endobarrier treatment in obese subjects with tdm endobarrier gastrointestinal liner  study of metabolic effects of endobarrier versus intragastric balloon in obese patients with type  diabetes endobarrier liner with endobarrier restrictor  product status endobarrier liner with endobarrier restrictor  product description gi dynamics inc key employees gi dynamics inc other locations list of figures gi dynamics inc pipeline products by equipment type gi dynamics inc pipeline products by development stage gi dynamics inc clinical trials by trial status  request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send gi dynamics inc gid  product pipeline analysis trends share size research report uscanada toll free home globaldata surgical equipment gi dynamics inc gid  product pipeline analysis gi dynamics inc gid  product pipeline analysis published by  globaldata published date  nov  category  surgical equipment no of pages   pages description table of content check discount gi dynamics inc gi dynamics is a medical device company it undertakes the development and commercialization of nonsurgical treatments for the global patient population suffering with type  diabetes and obesity the companys key product endobarrier therapy is used for the treatment of type  diabetes and obesity the product doesnt depend on medication or involve surgery to help patients regain control of type  diabetes and obesity endobarrier device is placed in the intestine by a small tube which is inserted by the mouth acting as a physical barrier between food and that part of the intestine where it is placed it delays digestion and intervenes with the bodys metabolic functions resulting in improved diabetes control and weight loss the company offers its product in selected regions of europe south america and australia gi dynamics is headquartered in lexington massachusetts the us this report is a source for data analysis and actionable intelligence on the gi dynamics inc portfolio of pipeline products the report provides detailed analysis on each pipeline product with information on the indication the development stage trial phase product milestones pipeline territory estimated approval date and estimated launch date each pipeline product is profiled to cover information on product description function technology indication and application the report is also supplemented with a detailed company profile and information on clinical trials wherever applicable this report is built using data and information sourced from proprietary databases primary and secondary research and inhouse analysis by globaldatas team of industry experts scope detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments detailed coverage on all the pipeline products by equipment type by therapy area by development stage and by trial phase information on product milestones and pipeline territory for each product the estimated approval date and estimated launch date profile of each pipeline product with additional information on product description function technology indications and application data on relevant clinical trials and product patent details wherever applicable information on clinical trial wherever applicable is supplemented with information on trial phase trial status trial objective trial design target patients unique physician identifier primary point secondary point acronym participants inclusion participants exclusion interventions trial results trial start date trial end date study type trial site trial funding age eligibility and gender eligibility reasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally design and develop your product development marketing and sales strategies exploit ma opportunities by identifying market players with the most innovative pipeline develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials stage and phase of development etcwhich are the next highvalue products that your competitor would add in its portfolio identify understand and capitalize table of content table of contents list of tables list of figures  key facts  gi dynamics inc pipeline products by equipment type gi dynamics inc pipeline products by development stage gi dynamics inc pipeline products by therapy area gi dynamics inc pipeline products by trial phase gi dynamics inc pipeline products by milestone summary endobarrier flow restrictor endobarrier flow restrictor product status endobarrier flow restrictor product description endobarrier flow restrictor product milestone endobarrier flow restrictor clinical trial endobarrier gastrointestinal liner endobarrier gastrointestinal liner product status endobarrier gastrointestinal liner product description endobarrier gastrointestinal liner clinical trial endobarrier liner with endobarrier restrictor endobarrier liner with endobarrier restrictor product status endobarrier liner with endobarrier restrictor product description endobarrier liner with endobarrier restrictor clinical trial gi dynamics inc  key competitors gi dynamics inc  key employees gi dynamics inc  locations and subsidiaries head office other locations  subsidiaries recent developments gi dynamics inc recent developments aug   gi dynamics receives fda conditional approval for pivotal clinical trial of endobarrier jun   gi dynamics announces presention of clinical data of endobarrier therapy at th annual meeting of asmbs apr   gi dynamics expands global commercial team feb   gi dynamics reports  results nov   gi dynamics appoints mark twyman as its chief commercial officer nov   gi dynamics appoints robert solomon as vice president finance  appendix methodology about globaldata contact us disclaimer  list of table gi dynamics inc key facts gi dynamics inc key pipeline products by equipment type gi dynamics inc key pipeline products by therapy area gi dynamics inc key pipeline products by development stage gi dynamics inc key pipeline products by trial phase gi dynamics inc key facts gi dynamics inc number of pipeline products by equipment type gi dynamics inc pipeline products by equipment type gi dynamics inc number of pipeline products by development stage gi dynamics inc pipeline products by development stage gi dynamics inc number of pipeline products by therapy area gi dynamics inc pipeline products by therapy area gi dynamics inc number of pipeline products by trial phase gi dynamics inc pipeline products by trial phase gi dynamics inc number of pipeline products by milestone summary gi dynamics inc pipeline products by milestone summary endobarrier flow restrictor  product status endobarrier flow restrictor  product description endobarrier flow restrictor  product milestone endobarrier flow restrictor  a pilot trial of the endobarrier flow restrictor for glycemic improvement in type  diabetics endobarrier gastrointestinal liner  product status endobarrier gastrointestinal liner  product description endobarrier gastrointestinal liner  endobarrier investigational treatment in reduction of ac in patients with diabetes mellitustype endobarrier gastrointestinal liner  interim report on a prospective randomized sham controlled trial investigating a completely endoscopic duodenaljejunal bypass sleeve for the treatment of type  diabetes endobarrier gastrointestinal liner  an open label randomized controlled study of a second generation endobarrier liner vs diet control for the treatment of type  diabetes endobarrier gastrointestinal liner  a multicenter randomized clinical trial to examine the safety and efficacy of the endobarrier in morbidly obese patient endobarrier gastrointestinal liner  post marketing study in subjects who have type  diabetes using the endobarrier gastrointestinal liner endobarrier gastrointestinal liner  a pilot trial of obese subjects previously implanted with the endobarrier gastrointestinal liner endobarrier gastrointestinal liner  a pilot trial of the gi endobarrier liner for short term weight loss in subjects who are candidates for bariatric surgery endobarrier gastrointestinal liner  phase ii singlecenter prospective open label efficacy study of the gi endobarrier liner for the treatment of type  diabetes endobarrier gastrointestinal liner  randomized efficacy study on endobarrier in gi hormones key to improve glycemic control endobarrier gastrointestinal liner  a pivotal clinical trial for endobarrier in patients with uncontrolled type  diabetes endobarrier gastrointestinal liner  a randomized multicenter pivotal efficacy and safety study comparing the endobarrier gastrointestinal liner system vs sham for glycemic improvement in inadequately controlled obese type  diabetic subjects on metformin andor sulfonylurea antidiabetes agents endobarrier liner with endobarrier restrictor  product status endobarrier liner with endobarrier restrictor  product description endobarrier liner with endobarrier restrictor  endo barrier treatment in obese subjects with type  diabetes mellitus tdm gi dynamics inc key employees gi dynamics inc other locations  list of chart gi dynamics inc pipeline products by equipment type gi dynamics inc pipeline products by development stage gi dynamics inc pipeline products by therapy area gi dynamics inc pipeline products by trial phase gi dynamics inc pipeline products by milestone summary  make an enquiry before buying this report please fill the enquiry form below full name  your email  job title  company  phone no  pls affix country code message security code   choose license type  select user license single license user  multiple license user  do you wish to check sample of this report order a sample report have query on this report related news zinc prices to continue to shoot as hopes of output rise remain bleak shift to cloudbased products and services fares well for microsoft india remains leading provider of online labors in technology and software development sector flipkart’s phonepe ventures in india’s offline space india introduces first train powered by solar power research assistance we will be happy to help you find what you need please call us or write to us  uscanada toll free tel   email  salesresearchmozus gi dynamics inc gid  product pipeline analysis  update sales and support     uk     us infomarketpublisherscom business  finance retail retail consumer goods food  beverage industry chemicals it  technology life sciences services about faq my cart market reports pressreleases events about us terms  conditions customer faq market research reports company reports gi dynamics inc gid  product pipeline analysis  update date november   pages  price us  license  single user price  us  site license price  us  enterprisewide price global site license  us  publisher globaldata report type strategic report delivery email delivery pdf id gcbaaaen leaflet download pdf leaflet abstracts contents list of tables list of figures summarygi dynamics inc gi dynamics is a medical service provider that develops and commercializes nonsurgical treatments for patients the company’s product includes endobarrier therapy its product endobarrier is an endoscopically delivered device therapy that is designed to mimic the mechanisms of metabolic surgerywithout altering the anatomy gi dynamics’s endobarrier therapy affects hormones involved in insulin sensitivity glucose metabolism satiety and food intake and delivers its therapeutic effect directly to target organs the company’s products are used for the treatment of type  diabetes and obesity it markets its products through distributors in australia south america and europe gi dynamics is headquartered in lexington massachusetts the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescopethe report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developmentsthe report analyzes all pipeline products in development for the company gi dynamics incthe report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial statusthe report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch datethe report provides detailed description of products in development technical specification and functionsthe report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design trial status and phase estimated start and end datereasons to buydevelop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscapedesign and develop your product development marketing and sales strategies by understanding the competitor portfolioto formulate effective research  development strategiesdevelop marketentry and market expansion strategiesexploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust returnplan mergers and acquisitions effectively by identifying key players of the most promising pipeline identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantagedevelop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etcidentify understand and capitalize the next highvalue products that your competitor would add in its portfolio gi dynamics inc company snapshotgi dynamics inc company overviewkey informationgi dynamics inc pipeline products and clinical trials overviewgi dynamics inc  major products and servicesgi dynamics inc pipeline products by development stagegi dynamics inc clinical trials by trial statusgi dynamics inc pipeline products overviewendobarrier flow restrictorendobarrier flow restrictor product overviewendobarrier gastrointestinal linerendobarrier gastrointestinal liner product overviewendobarrier gastrointestinal liner clinical trialendobarrier liner with endobarrier restrictorendobarrier liner with endobarrier restrictor product overviewendobarrier liner with endobarrier restrictor clinical trialgi dynamics inc  key competitorsgi dynamics inc  key employeesgi dynamics inc  locations and subsidiarieshead officeother locations  subsidiariesrecent developmentsgi dynamics inc recent developmentssep   german diabetes society rele ases statement regarding gi dynamics’ terminatio n of us endo trialjul   gi dynamics appendix c quarterly report quarter ended  june jul   gi dynamics concludes endo trialjul   gi dynamics concludes endo trialjun   gi dynamics announces departure of chief medical officerjun   new data presented at ada demonstrate early effect of endobarrier therapy on glucose control and bile acid regulatorsmay   gi dynamics announces results of first comparative study of gastric bypass and endobarrier therapy on diabetes remission at digestive disease week mar   endo trial placed on enrollment holddec   gi dynamics announces corporate restructuring and departure of chief financial officerdec   gi dynamics resumes shipments of endobarrier productappendixmethodologyabout globaldatacontact usdisclaimer list of tablesgi dynamics inc key factsgi dynamics inc pipeline products and clinical trials overviewgi dynamics inc pipeline products by equipment typegi dynamics inc pipeline products by indicationgi dynamics inc clinical trials by trial statusgi dynamics inc major products and servicesgi dynamics inc number of pipeline products by development stagegi dynamics inc pipeline products summary by development stagegi dynamics inc clinical trials by trial statusgi dynamics inc clinical trials summaryendobarrier flow restrictor  product statusendobarrier flow restrictor  product descriptionendobarrier gastrointestinal liner  product statusendobarrier gastrointestinal liner  product descriptionendobarrier gastrointestinal liner  a pilot trial of the gi endobarrier liner for short term weight loss in subjects who are candidates for bariatric surgeryendobarrier gastrointestinal liner  a randomized controlled trial of a duodenal sleeve bypass device endobarriercompared with standard medical therapy for the management of obese subjects with type  diabetesendobarrier gastrointestinal liner  endobarrier treatment in obese subjects with tdmendobarrier gastrointestinal liner  endobarrier vs conventional therapy in the management of metabolic syndrome in obese patients medicoeconomic analysis as part of a randomized controlled multicenter trial  endometabendobarrier gastrointestinal liner  study of metabolic effects of endobarrier versus intragastric balloon in obese patients with type  diabetesendobarrier gastrointestinal liner  the endocrine impact of the duodenaljejunal bypass sleeve on type  diabetes  potential role of the incretin hormonesendobarrier liner with endobarrier restrictor  product statusendobarrier liner with endobarrier restrictor  product descriptionendobarrier liner with endobarrier restrictor  the effect of the endobarrier device a year follow up of a randomized clinical trialgi dynamics inc key employeesgi dynamics inc other locations list of figuresgi dynamics inc pipeline products by equipment typegi dynamics inc pipeline products by development stagegi dynamics inc clinical trials by trial status skip to top more publications metastat inc mtst  product pipeline analysis  update us  jun  ·  pages opko health inc opk  product pipeline analysis  update us  may  ·  pages vascular solutions inc vasc  product pipeline analysis  update us  may  ·  pages alphatec holdings inc atec  product pipeline analysis  update us  may  ·  pages ask your question gi dynamics inc gid  product pipeline analysis  update company name contact person phonefax email request invoice your enquiry please click on a check box below to confirm you are not a robot market reports all categories sales and support         infomarketpublisherscom   marketpublisherscom about us our clients our publishers customer faq market reports new publications reports by regions pressreleases terms  conditions privacy policy return policy affiliate program join as publisher follow us gi dynamics inc gid  product pipeline analysis  update by globaldata market research report at marketreportsonlinecom welcome guest  register  login      salesmarketreportsonlinecom home  company profiles  report detail gi dynamics inc gid  product pipeline analysis  update report description table of contents faqs summary gi dynamics inc gi dynamics is a medical device company the company develops and commercializes nonsurgical treatments for the global patient population suffering with type  diabetes and obesity its product endobarrier therapy is used for the treatment of type  diabetes and obesity gi dynamics conducts clinical trial of endobarrier the endo trial in the us the companys product lowers blood glucose levels and promotes weight loss in diabetic patients andor obese patients during the implant period it sells products in europe south america and australia gi dynamics is headquartered in lexington massachusetts the us this report is a source for data analysis and actionable intelligence on the companys portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage scope  the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments  the report analyzes all pipeline products in development for the company gi dynamics inc  the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status  the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date  the report provides detailed description of products in development technical specification and functions  the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end date reasons to buy  develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape  design and develop your product development marketing and sales strategies by understanding the competitor portfolio  to formulate effective research  development strategies  develop marketentry and market expansion strategies  exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return  plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials stage and of development etc  identify understand and capitalize the next highvalue products that your competitor would add in its portfolio single user license report will be emailed in pdf format and can be accessed by a specific user this license type allows the report to be printed site license report will be emailed in pdf and  allows only employees within the same geographical location within the organization to access it this license type allows the report to be printed global site license report will be emailed in pdf format and allows all employees within the organization to access it  this license type allows the report to be printed why httpwwwmarketreportsonlinecom gi dynamics inc gid  product pipeline analysis  update published by globaldata price single user license us   site license us   global site license us   how to purchase purchase reports from our site in few easy clicks please follow the description given below to complete your purchase process step  select the report title of your interest and click on buy now button next to the price option step  you will arrive at the purchase page where you will be requested to signup new user or login registered user please note that inkeeping with the security check on the website you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information step  after signuplogin you will arrive at our payment page on paypal you will see your order summary as well as an option to choose a way to pay select a payment option from pay with a paypal account or pay with a debit or credit card marketreportonline accepts visa mastercard american express and discover through paypal fill up the required details in the option of your choice step  once you follow the required process in step  as mentioned above you have successfully completed the purchase process step  once you have successfully completed the purchase process you will receive a confirmation email the report will then be emailed to you directly by the publisher as per our agreement with the publisher for orders that are placed after working hours the delivery of the reports will be made on the next business day for orders that are placed during weekends the delivery of the reports will be made on the next working business day please note if you select purchase by invoice you will receive your report only once the payment has been received if you have any queries about how to order please contact us price  single user license us   site license us   global site license us   published sep  no of pages  subscription option using our subscription option you get access to market research reports and industry data of company profiles market as per your needs get the best of company profiles research reports by utilizing your research budgets in an optimum way contact salesmarketreportsonlinecom for details email alert get email alerts about market research reports from industries and publishers of your interest market insights top banking trends the current trend include some of the key trends from last year with new trends in the areas of customer experience digital and mobile delivery digital payments innovation alternative products auth global tea market propelled by high green and black tea demands tea is the most popular beverages consumed globally the biggest share of tea consumption is mostly local in the country or region of production the tea industry is characterized by a few corporations monitoring the comp telehealth is the biggest revolution in healthcare telehealth is a very effectual way to consume medical care and it is bound for growth over time telehealth services expenditure in the us is estimated to catapult nearly ten times in the coming years forecasts are that  gi dynamics inc provides  business outlook and  review  business wire gi dynamics inc provides  business outlook and  review january    am eastern standard time boston  sydneybusiness wiregi dynamics inc asxgid a medical device company that has commercialized endobarrier® in europe for patients with type  diabetes and obesity today released a  business outlook and recap of  accomplishments  marks the first full calendar year with the company’s new management team following the  appointment of scott schorer as president and ceo schorer subsequently appointed industry veteran jim murphy as chief financial officer and brian callahan as chief compliance officer to help usher in a new era and reestablish key corporate priorities in driving commercial growth of endobarrier® the first endoscopicallydelivered device therapy for the treatment of type  diabetes and obesity in addition dan moore an experienced medical device executive was named chairman last year and oern stuge md mba was appointed to the board at the beginning of the  “there is a significant need for effective therapeutic options for the more than  million patients worldwide with type  diabetes and obesity” said schorer “with more than  implants shipped as of yearend  and a growing body of evidence demonstrating meaningful reductions in hemoglobin ac hbac levels and weight our focus this year is on enhancing commercialization in the united kingdom germany and the middle east building on and harnessing the growing body of efficacy and safety data and continuing dialogue with the fda toward us regulatory approval” priorities for  include the following gi dynamics will support commercialization market access and reimbursement efforts underway in the united kingdom germany the middle east and select european countries gi dynamics will continue building relationships with regulatory agencies in europe and the united states especially as the company finalizes the protocol for its pivotal us investigational device exemption ide trial in anticipation of initiating and beginning to enroll the trial this year gi dynamics will raise capital to secure funding for executing us clinical development and commercial plans gi dynamics will establish a scientific advisory board comprised of leading experts in treatment and management options for patients with type  diabetes and obesity to aid both clinical development and commercial strategies gi dynamics will bolster the efficacy and safety profile for endobarrier with presentations and publications based on data generated from multiple postmarketing and investigatorinitiated studies gi dynamics will continue to evolve and add to its team highlights from  the new leadership team began work immediately by slashing costs across the board to stabilize the company and extend the cash runway through the end of q  a  million placement on the asx in december together with a security purchase plan spp investment vehicle which is still in process should allow us sufficient capital to operate the company through the end of  the company expects to continue to operate on a lean basis with regard to cash burn in  gi dynamics made promising clinical advancements through continued support of investigatorinitiated studies worldwide and strengthened regulatory relationships with the fda and its european notified body the company also announced positive data demonstrating improved outcomes in both ac and weight reduction as well as reinforcing the endobarrier safety profile in addition to revamping the management team the company made significant strides in streamlining operations and reducing expenses specific accomplishments include the following gi dynamics continued to build its intellectual property protection around endobarrier—the company was granted a total of eight allowances for patents from the us patent office and the european patent office gi dynamics presented data from the german endobarrier registry during the annual meeting of the european association for the study of diabetes from  patients showing clinically relevant results data indicated a lowering of the absolute ac mean from  percent to  percent in concert with a lowering of antidiabetic medication in  percent of patients while reducing the dose of insulin by  percent on a mean basis gi dynamics presented results of the endo trial at the american diabetes association’s ada’s th scientific sessions that demonstrated clinically meaningful improvements in ac levels and weight reduction compared with the shamtreated group these outcomes were achieved with only  of the planned  subjects being randomized into the trial because the company halted the trial due to a higher than anticipated rate of hepatic abscess ha the overall safety profile was positive and of note no adverse events led to longterm sequelae or mortality the data presented included the following statistically and clinically significant efficacy— percent absolute reduction in hbac statistically and clinically significant efficacy— percent reduction in body weight and data showed that  percent of patients achieved the ada target of ac ≤  percent after  months the company expects to continue releasing new clinical information on a regular basis throughout  “building on this clinically meaningful data and developing and enhancing relationships with investigators providers and patients will help continue to expand the clinical support for endobarrier and help expand access to treatment” said schorer “we are well on our way towards achieving the clinical regulatory commercial and operational goals we set out to accomplish at the outset and look forward to sharing that news with the market” about gi dynamics gi dynamics inc asxgid is the developer of endobarrier the first endoscopicallydelivered device therapy approved for the treatment of type  diabetes and obesity endobarrier is approved and commercially available in multiple countries outside the united states endobarrier is not approved for sale in the united states and is limited by federal law to investigational use only in the united states founded in  gi dynamics is headquartered in boston massachusetts for more information please visit wwwgidynamicscom forwardlooking statements this announcement contains forwardlooking statements concerning our development and commercialization plans potential revenues and revenue growth costs excess inventory profitability and financial performance ability to obtain reimbursement for our products clinical trials and associated regulatory submissions and approvals the number and location of commercial centers offering the endobarrier and our intellectual property position these forwardlooking statements are based on gi dynamics’ management’s current estimates and expectations of future events as of the date of this announcement furthermore the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the consequences of terminating the endo trial and the possibility that future clinical trials will not be successful or confirm earlier results further risks are associated with obtaining funding from third parties the timing and costs of clinical trials the timing of regulatory submissions and the timing receipt and maintenance of regulatory approvals the timing and amount of other expenses and the timing and extent of thirdparty reimbursement risks associated with commercial product sales including product performance competition risks related to market acceptance of products intellectualproperty risk risks related to excess inventory and risks related to assumptions regarding the size of the available market the benefits of our products product pricing timing of product launches future financial results and other factors including those described in our filings with the us securities and exchange commission given these uncertainties one should not place undue reliance on these forwardlooking statements we do not assume any obligation to publicly update or revise any forwardlooking statements whether as a result of new information or future events or otherwise unless we are required to do so by law contacts investor relationsgi dynamics incunited statesmonica bellevue   contacts investor relationsgi dynamics incunited statesmonica bellevue   search advanced news search advanced news search log in sign up gi dynamics inc provides  business outlook and  reviewhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health caregi dynamics inc provides  business outlook and  reviewbusiness wirejanuary  reblogsharetweetshareboston  sydneybusiness wiregi dynamics inc gidax a medical device company that has commercialized endobarrier® in europe for patients with type  diabetes and obesity today released a  business outlook and recap of  accomplishments marks the first full calendar year with the company’s new management team following the  appointment of scott schorer as president and ceo schorer subsequently appointed industry veteran jim murphy as chief financial officer and brian callahan as chief compliance officer to help usher in a new era and reestablish key corporate priorities in driving commercial growth of endobarrier® the first endoscopicallydelivered device therapy for the treatment of type  diabetes and obesity in addition dan moore an experienced medical device executive was named chairman last year and oern stuge md mba was appointed to the board at the beginning of the “there is a significant need for effective therapeutic options for the more than  million patients worldwide with type  diabetes and obesity” said schorer “with more than  implants shipped as of yearend  and a growing body of evidence demonstrating meaningful reductions in hemoglobin ac hbac levels and weight our focus this year is on enhancing commercialization in the united kingdom germany and the middle east building on and harnessing the growing body of efficacy and safety data and continuing dialogue with the fda toward us regulatory approval”priorities for  include the following gi dynamics will support commercialization market access and reimbursement efforts underway in the united kingdom germany the middle east and select european countries gi dynamics will continue building relationships with regulatory agencies in europe and the united states especially as the company finalizes the protocol for its pivotal us investigational device exemption ide trial in anticipation of initiating and beginning to enroll the trial this year gi dynamics will raise capital to secure funding for executing us clinical development and commercial plans gi dynamics will establish a scientific advisory board comprised of leading experts in treatment and management options for patients with type  diabetes and obesity to aid both clinical development and commercial strategies gi dynamics will bolster the efficacy and safety profile for endobarrier with presentations and publications based on data generated from multiple postmarketing and investigatorinitiated studies gi dynamics will continue to evolve and add to its team highlights from the new leadership team began work immediately by slashing costs across the board to stabilize the company and extend the cash runway through the end of q  a  million placement on the asx in december together with a security purchase plan spp investment vehicle which is still in process should allow us sufficient capital to operate the company through the end of  the company expects to continue to operate on a lean basis with regard to cash burnin  gi dynamics made promising clinical advancements through continued support of investigatorinitiated studies worldwide and strengthened regulatory relationships with the fda and its european notified bodythe company also announced positive data demonstrating improved outcomes in both ac and weight reduction as well as reinforcing the endobarrier safety profile in addition to revamping the management team the company made significant strides in streamlining operations and reducing expensesspecific accomplishments include the following gi dynamics continued to build its intellectual property protection around endobarrier—the company was granted a total of eight allowances for patents from the us patent office and the european patent office gi dynamics presented data from the german endobarrier registry during the annual meeting of the european association for the study of diabetes from  patients showing clinically relevant results data indicated a lowering of the absolute ac mean from  percent to  percent in concert with a lowering of antidiabetic medication in  percent of patients while reducing the dose of insulin by  percent on a mean basis gi dynamics presented results of the endo trial at the american diabetes association’s ada’s th scientific sessions that demonstrated clinically meaningful improvements in ac levels and weight reduction compared with the shamtreated group these outcomes were achieved with only  of the planned  subjects being randomized into the trial because the company halted the trial due to a higher than anticipated rate of hepatic abscess ha the overall safety profile was positive and of note no adverse events led to longterm sequelae or mortality the data presented included the following statistically and clinically significant efficacy— percent absolute reduction in hbac statistically and clinically significant efficacy— percent reduction in body weight and data showed that  percent of patients achieved the ada target of ac ≤  percent after  months the company expects to continue releasing new clinical information on a regular basis throughout “building on this clinically meaningful data and developing and enhancing relationships with investigators providers and patients will help continue to expand the clinical support for endobarrier and help expand access to treatment” said schorer “we are well on our way towards achieving the clinical regulatory commercial and operational goals we set out to accomplish at the outset and look forward to sharing that news with the market”about gi dynamicsgi dynamics inc gidax is the developer of endobarrier the first endoscopicallydelivered device therapy approved for the treatment of type  diabetes and obesity endobarrier is approved and commercially available in multiple countries outside the united states endobarrier is not approved for sale in the united states and is limited by federal law to investigational use only in the united states founded in  gi dynamics is headquartered in boston massachusetts for more information please visit wwwgidynamicscomforwardlooking statementsthis announcement contains forwardlooking statements concerning our development and commercialization plans potential revenues and revenue growth costs excess inventory profitability and financial performance ability to obtain reimbursement for our products clinical trials and associated regulatory submissions and approvals the number and location of commercial centers offering the endobarrier and our intellectual property position these forwardlooking statements are based on gi dynamics’ management’s current estimates and expectations of future events as of the date of this announcement furthermore the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the consequences of terminating the endo trial and the possibility that future clinical trials will not be successful or confirm earlier results further risks are associated with obtaining funding from third parties the timing and costs of clinical trials the timing of regulatory submissions and the timing receipt and maintenance of regulatory approvals the timing and amount of other expenses and the timing and extent of thirdparty reimbursement risks associated with commercial product sales including product performance competition risks related to market acceptance of products intellectualproperty risk risks related to excess inventory and risks related to assumptions regarding the size of the available market the benefits of our products product pricing timing of product launches future financial results and other factors including those described in our filings with the us securities and exchange commission given these uncertainties one should not place undue reliance on these forwardlooking statements we do not assume any obligation to publicly update or revise any forwardlooking statements whether as a result of new information or future events or otherwise unless we are required to do so by lawview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextmany people dont even know they have this diseaseaolcommercks biosimilar insulin gets tentative fda approvalzackswhy sparkling water sales could spike by  in yahoo financewhat its like to ship yourself overnight on cabins sleep pod bustechcrunchintercepted communications appear to contradict jeff sessions claims about his conversations with russian ambassadorbusiness insideraetna ceo bertolini how tech plays into the future of healthcareyahoo finance videowhy it might be ‘dangerous’ for ibm to turn itself around professoryahoo financeaetnas ceo mark bertolini on the future of the health care systemyahoo financefund manager explains why he estimates putins net worth to be  billionyahoo financedivided uk inconclusive election could put brakes on brexitassociated pressaetna ceo bertolini why he pays his employees to sleepyahoo finance videocall of the week nows the time to buy chipotleyahoo financeboth men had enough of each other why sean spicer is really leaving trumps white housebusiness insideran obscure senate rule just put the gop healthcare bill in even bigger perilbusiness insidermissing malaysia airlines flight search yields valuable seafloor dataengadgetaetna ceo bertolini how his own accident and son’s cancer changed his journeyyahoo finance videodemocrats herald agreement on sweeping russia sanctions billmichaels what about a bill preventing trump from making any decisionsjoin the conversation  k gi dynamics inc executives organizational chart company profile information contacts  headquarters locations news submit contactcareerslogin menutoggle our difference research client successwho we serve sales professionals marketing professionals executives recruitingstaffing professionalssolutions column abm  abs actionable intelligence competitive intelligence customer success  retention column data quality  management data sets integrations lead generation column predictive analytics sales  marketing alignment targeting  ranking knowledge hub blog case studies insights faqsabout careers news pricing menu homeour difference research client successwho we serve sales professionals marketing professionals executives recruitingstaffing professionalssolutions abm  abs actionable intelligence competitive intelligence customer success  retention data quality  management data sets integrations lead generation predictive analytics sales  marketing alignment targeting  rankingknowledge hub blog case studies insights faqsabout careers news pricingget a free profileschedule a demorequest pricingcontact uslogin home  companies  gi dynamics inc gi dynamics inc  congress street th floor boston ma  united states phone   fax httpgidynamicscom  managers  it employees mest it budget gi dynamics inc is the developer of endobarrier a product which is approved for the treatment of type  diabetes and obesity sector industry healthcare  pharmaceuticals biotech and pharmaceuticals employees  revenue m fye  breaking news on investment signals date type inside scoop want full access to this profile and more rainkings clients have access to over  new investment signals published daily which provide insights on spending initiatives pain points management changes and more from companies around the globe interested in becoming a client request a demo request a quote technologies currently being used it marketing data analytics databases web analytics data infrastructure hosting hostasaurus information mgmt content management wordpress information security application security spf secure gateway parallels ssl network telecom systems network infrastructure microsoft azure dns this is just a subset of the full technolgies being used by this company this is just a subset of the full technolgies being used by this company become a rainking poweruser today rainkings rich data provides clients with a deeper understanding of who will be making – and what will be driving – upcoming investments in it know what your prospects are planning before your competition does and beat them to the negotiating table request a demo request a quote org chart of it decision makers scott schorer president and chief executive officer ceo gidynamicscom   jim murphy chief financial officer cfo gidynamicscom   karl blohm vice president international operations gidynamicscom   this is just a subset of the full org chart for this company want access to this and more become a client today rainking clients get access to all  decision makers in this companys org chart request a demo request a quote want full access to this profile and more rainkings clients have access to over  new investment signals published daily which provide insights on spending initiatives pain points management changes and more from companies around the globe interested in becoming a client request a demo request a quote to receive a free pdf of this company simply fill out the form below get your free company profile search subscribe to our newsletter connect with us  old georgetown road bethesda md   contactusrainkingonlinecom sitemap terms of use privacy policy  rainking